Thymosin Alpha-1
The Master Immune Regulator
A naturally occurring thymic peptide that enhances immune function, used clinically for infections, cancer support, and immunodeficiency.
Research Compound
About Thymosin Alpha-1
Thymosin Alpha-1 (Tα1) is a peptide naturally produced by the thymus gland that plays a central role in immune system regulation. It's approved in over 35 countries for treating hepatitis B, hepatitis C, and as an immune adjuvant in cancer therapy. Thymosin Alpha-1 enhances the function of dendritic cells, T-cells, and natural killer cells while also having direct antimicrobial properties. It's increasingly used in longevity protocols to maintain robust immune function with aging, when the thymus naturally atrophies and immune competence declines.
Mechanism of Action
Thymosin Alpha-1 acts primarily on dendritic cells and T-lymphocytes, enhancing their maturation, activation, and function. It increases the production of cytokines like IL-2 and IFN-γ that coordinate immune responses. Tα1 also enhances the expression of MHC class I molecules, improving the immune system's ability to recognize and destroy infected or cancerous cells. Additionally, it has direct antibacterial and antifungal properties.
How Thymosin Alpha-1 Works in Your Body:
- Target Receptors: Thymosin Alpha-1 binds to specific receptors that trigger downstream signaling cascades related to its primary benefits.
- Physiological Response: The body responds by modulating natural processes—whether hormone release, tissue repair, or cellular signaling—without replacing endogenous function.
- Timeline: Effects typically begin within a few days, with optimal results seen over the recommended protocol duration.
Dosing Protocol
Frequency
2-3 times per week for maintenance, daily during acute illness
Timing
Any time of day
Duration
Ongoing for immune support, or during illness
Important Notes
1.6-3.2mg subcutaneously. Clinical protocols often use 1.6mg twice weekly. Higher doses (3.2mg daily) during acute infections. Very safe with decades of clinical use.
Clinical Research
3 studies on Thymosin Alpha-1
Hepatitis B Treatment
Thymosin Alpha-1 combined with interferon improved viral clearance rates in chronic hepatitis B patients.
Hepatology
Cancer Immunotherapy
Tα1 enhanced the efficacy of cancer vaccines and checkpoint inhibitors in clinical trials.
Cancer Immunology, Immunotherapy
COVID-19 Support
Thymosin Alpha-1 reduced mortality in severe COVID-19 patients by improving T-cell counts and function.
Clinical Infectious Diseases
Important Safety Information
Medical Disclaimer: The information provided about Thymosin Alpha-1 is for educational purposes only and is not intended as medical advice. Always consult with a qualified healthcare provider before starting any new supplement or peptide protocol.
Research Status: While Thymosin Alpha-1 has shown promising results in research studies, many peptides are still being studied and may not be approved by regulatory bodies like the FDA for specific uses. The research cited represents ongoing scientific investigation.
Individual Variation: Responses to peptides vary significantly between individuals. What works for one person may not work for another. Side effects, while generally mild, can occur and should be monitored closely.
Quality & Sourcing: If you choose to use peptides, ensure you obtain them from reputable, tested sources. Peptide quality, purity, and proper storage are critical for safety and efficacy.
Legal Considerations: Peptide regulations vary by country and jurisdiction. Some peptides may require a prescription or may have restrictions on their use. Research the laws in your area before obtaining or using peptides.